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Abstract 
Introduction: Albuminuria class transition (normo- to micro- to macroalbuminuria) is used as 
an intermediate  surrogate endpoint to assess renoprotective drug efficacy. Current definitions 
of such class transition vary between trials in: number of urine collections, requirement of a 
confirmation visit and if so at what time, and the requirement of a minimal percentage 
albuminuria from baseline. We evaluated these different approaches to obtain the most optimal 
protocol. 
Methods: Four clinical trials testing the effect of renin-angiotensin-aldosterone-system 
intervention on albuminuria class transition in diabetic patients were included: BENEDICT, 
DIRECT, ALTITUDE and IRMA-2. Each trial used a different class transition definition based 
on: 1) either 1, 2, or 3 consecutively collected urine samples at each study visit, 2) different 
time intervals between study visits, 3) requirement of an additional visit to confirm the class 
transition, and 4) requirement of a percentage increase in albuminuria from baseline in addition 
to the class transition. We tested the effect of these different definitions on drug efficacy 
outcomes by Cox regression analysis. 
Results: Neither increasing the number of urines collected at a single study visit, nor the time 
interval between study visits, nor the requirement of a subsequent confirmation visit, nor the 
addition of a minimal percentage albuminuria change from baseline altered the average drug 
effect. However, the standard error of the treatment effect increased (decreased precision) with 
stricter endpoint definitions resulting in a loss of statistical significance. 
Conclusion: The optimal albuminuria transition endpoint for use in drug intervention trials can 
use a single urine collection for albuminuria assessment per study visit. A, without 
confirmation of the end point, and or with noa requirement of a minimal percentage change in 
albuminuria from baseline is not necessary. 
 
 
3 
 
Introduction 
Transition in albuminuria class (normo- to micro- or micro- to macroalbuminuria) is a hallmark 
of progression of diabetic kidney disease.1,2 This hallmark has been used as an endpoint in 
clinical trials to assess renoprotective efficacy of clinical interventions. Since there is no 
standardized protocol how to measure an albuminuria class transition,  different definitions 
have been used in past trials3,4,5,6,7,8 , varying in the way urine was collected (first morning void 
vs. spot urine),3,8 how albuminuria was expressed (urinary albumin excretion or 
albumin:creatinine ratio),3,6,8 the frequency and interval of urine collections to define a class 
transition,4,3,6 as well as the requirement for a confirmatory visit.3,4 Confirmation at a 
subsequent visit may be important, since albuminuria is known to show a large day-to-day 
variability.9,10 To ensure that a class change is not due to chance, the end point definition is 
often complemented with a requirement that albuminuria increase should be greater than a 
predefined percentage of baseline.3,4 
Harmonization of the endpoint criteria for the optimal definition of class transition in 
albuminuria is important for the design of future clinical trials. Defining a transition by a single 
measurement and without a predefined percentage change may increase the number of 
endpoints and thereby the statistical power to assess drug effects. However, a predefined 
percentage change and a subsequent confirmatory visit may decrease the number of endpoints 
but may increase the precision of the transition and thereby increase statistical power to assess 
drug effects.  
The aim of this study was therefore to weigh the importance of all these opposing effects 
in a post-hoc analysis of completed clinical trials, which tested the effects of RAAS-inhibition 
on albuminuria class transitions. The objective was to determine the optimal definition for a 
transition in albuminuria class regarding the frequency of urine collections, the interval 
between study visits for urine collections, the requirement of confirmatory visits, and the cut-
off threshold for the percentage change from baseline. 
 
Results 
Baseline characteristics of included trials are published elsewhere and are summarized in Table 
1.3,11,12,13  
 
Number of endpoints 
Increasing the number of urine collections per visit reduced the number of endpoints (Table 2). 
The number of endpoints further decreased in each trial when the transition endpoint required 
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a confirmation at a subsequent visit (Table 2). Adding increasing percentages of albuminuria 
change to the endpoint definition only marginally reduced the number of endpoints in each trial 
(Table 2).  
 
Number of urine collections at a single visit and time interval between visits 
Increasing the number of urine collections at a single visit only had minimal effect on the 
average treatment effect and 95% confidence interval in the BENEDICT, DIRECT and 
ALTITUDE trials (Figure 1). For example, in the BENEDICT trial, the hazard ratio was 0.60 
(95%CI 0.40 to 0.89) when the transition endpoints were calculated from the geometric mean 
of three consecutive urine samples at each visit and 0.66 (95%CI 0.46 to 0.99) based on single 
urine samples. Increasing the time interval between study visits for albuminuria assessment 
had no effect on the magnitude of the average treatment effect while the  precision of the drug 
effect estimate decreased somewhat as indicated by the wider confidence intervals (Supplement 
Figure 1). 
 
Requirement for confirmation visits and time interval of the confirmation visit 
Addition of a confirmation visit to firmly establish the class transition only minimally affected 
the average treatment effects of trandolapril, candesartan, irbesartan or aliskiren (Figure 2). 
However, the precision of the drug effect estimate markedly decreased as reflected by the wider 
95% confidence interval in all trials. For example, in the BENEDICT study, the hazard ratio 
was 0.66 (95%CI 0.46 to 0.99) when the transition endpoints were not confirmed and 0.60 
(95%CI 0.21 to 1.70) with confirmation. Despite the different time intervals of the 
confirmatory visit, a decrease in precision occurred in all trials suggesting that the timing of 
the confirmatory visit had no impact on the result. 
 
Percentage increase in albuminuria 
Enhancing the level of minimal percentage change in albuminuria from baseline from 10% to 
40100% had minimal impact on the average and standard error of the treatment effects of 
trandolapril, candesartan, irbesartan or aliskiren (Figure 3). For example in the BENEDICT 
study, the hazard ratio was 0.66 (95%CI 0.46 to 0.94) with 10% increase in albuminuria in 
addition to the class transition,  and 0.68 65 (95%CI 0.46 44 to 0.94) with 540% increase in 
albuminuria, and 0.54 (95%CI 0.36 to 0.81) with 100% increase in albuminuria. Hazard ratio’s 
were somewhat higher (smaller treatment effect) in most trials if the endpoint was based on a 
50% or 100% increase without class transition (Supplement Table 2).  
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Association between albuminuria class transition endpoints and clinical outcomes 
The ALTITUDE database was used to determine the association between a class transition in 
albuminuria, an intermediate endpoint, with subsequent clinical renal and cardiovascular 
outcomes. A transition in albuminuria stage from normo- to microalbuminuria or micro- to 
macroalbuminuria based on a single urine sample at a single visit was independently associated 
with a higher risk of the renal (HR 1.92 (95% CI 1.09 – 3.40; p=0·025) and cardiovascular 
endpoint (HR 1.45 (95% CI 1.15 – 1.83; p=0·002; Table 3). Hazard ratio's only marginally 
changed when the class transition was based on the average of multiple urine samples at a 
single visit, or when a confirmation visit or a percentage albuminuria increase to the endpoint 
definitions were added to define the class transition (Table 3). 
 
Discussion 
Transition of albuminuria class may become a more and more important (surrogate) end point 
to evaluate renoprotective drug effects. Its current use shows a wide variety of definitions of 
such an albuminuria class transition. The variations concerned the number of albuminuria 
collections per visit, the interval of study visits for albuminuria collection, the addition of a 
class-change-conformation visit, and the addition of a minimal percentage albuminuria change 
with the class transition. We established in a post hoc analysis of four randomized controlled 
clinical trials that none of these variations had a significant impact on most of the outcome 
parameters in the different studies. These data suggest that single urine collections at a study 
visit are sufficient to define a transition in albuminuria as an endpoint in clinical trials.  
Because of the within individual day-to-day fluctuations in albuminuria prior clinical 
trials have used the average albuminuria from three consecutive instead of one urine collection 
at each study visit to determine a transition in albuminuria stage. In our study we found that 
decreasing the number of urine samples at a single visit led to a small increase in the number 
of endpoints, but the average drug effect and the precision of the drug effect did not change. It 
is likely that when using single urine samples a potential increase in the precision of the drug 
effect estimate (as a result of the higher number of endpoints) is balanced by introducing 
random noise and false positive endpoints so that the average drug effect and precision does 
not change.  An increase in the number of endpoints would be expected to result in an increase 
in precision of the drug effect estimate (decreased standard error) and increase in statistical 
significance. Yet, this did not occur possibly because using single compared to triple urine 
samples to define the endpoint may have introduced random noise and false positive endpoints. 
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These two effects may have balanced each other so that the average and confidence intervals 
of the drug effect estimate did not change. This finding is in line with our previous study 
demonstrating that increasing the number of urine samples at a single visit had a modest effect 
on the precision of the albuminuria lowering drug effect estimate  
The results suggest that a time-interval of 6 months between study visits resulted in 
treatment effects of larger statistical significance compared to a 12 month time-interval 
between study visits. Unfortunately, urine collections did not occur more frequently than every 
6 months in all trials. We were therefore unable to determine whether shorter time-intervals 
between visits would lead to more significant treatment effects. This needs to be addressed in 
future studies.   
Another approach that has been used in clinical trials to attenuate minimize the impact 
of the within individual day-to-day fluctuations in albuminuria on the transition endpoint has 
been the requirement of a confirmation of the albuminuria transition. The addition of a 
confirmatory visit is expected to decrease the random noise in the treatment effect due to 
albuminuria fluctuations and false positive transitions. However, our analysis showed that 
adding a confirmatory visit to the endpoint definition led to a marked decrease in endpoints 
and decrease in precision of the drug effect estimates. The marked decrease in endpoints 
apparently overruled the potential gain in statistical power due to the removal of false-positive 
transitions. The timing of the confirmation visit for the albuminuria transition differed in each 
trial but the results were consistent regardless at what time the confirmation visit was 
conducted.   
  Previous trials have added a 30% increase in albuminuria when the transition occurs 
as a third strategy to reduce the influence of day-to-day albuminuria fluctuations and endpoint 
occurrence due to chance, particularly for patients whose baseline albuminuria levels are close 
to the transition threshold. The first trial that added a 30% albuminuria increase in albuminuria 
when the to the transition endpoint occurs was a trial on the effect of captopril in patients with 
type 1 diabetes.14 Although it seems logical to add an percentage increase in albuminuria to the 
endpoint definition to avoid that people close to the border of a class, can have class change 
with very small albuminuria changes, our results indicate that it had no effect on the number 
of endpoints, the average drug effect, nor on the precision of the drug effect.  
The question is whether a transition in albuminuria class, a surrogate, represents a hard 
outcome, and if so, whether a single-urine-determined-transition is as good as two or three-
consecutive-urine determined transitions for hard outcome prediction. Indeed in a post-hoc 
analysis of the ALTITUDE trial we found that a transition in albuminuria predicts renal and 
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cardiovascular outcomes (Supplement Table 1). In addition, the predictive powerassociation 
was independent of all different definitions that we used for the albuminuria class transition 
(Supplement Table 1). These data support using single urine samples at a single visit to define 
a transition endpoint.   
Standardization of clinical trial endpoint definitions is important for drug regulators, 
physicians, and patients to assess and compare clinical trial results and to interpret drug 
efficacy. Surprisingly, all past clinical trials have used different definitions for a class transition 
in albuminuria endpoint. The trials differed in the number of urine collections at each visit to 
determine urinary albumin excretion, the method of urine collection (timed overnight 
collections, first morning void collections), correction of urinary albumin concentration by 
urinary creatinine concentration, and requirement of a confirmation of the albuminuria 
transition. Due to the different definitions we unified the endpoint definitions across all 
included trials in order to compare different trial results. Since we standardized the endpoint 
definitions for the included trials, our results may differ from the published results in the 
original publications.  
These results may at first sight contrast our previous findings in which we concluded 
that increasing the frequency of urine collections during follow-up of a clinical trial increases 
the precision and statistical power to detect an albuminuria lowering drug effect.15 However, 
there are important differences between these studies. Firstly, the endpoints between the studies 
were different. In the present study the drug effect on a dichotomous outcome was determined. 
In trials with dichotomous outcomes the statistical power is determined by the proportion of 
patients who reach the outcome. In our prior study we evaluated the drug effect on the 
continuous outcome of percentage albuminuria change. In these trials the power is determined 
by the magnitude of change and standard deviation of the change. Second, the number of 
confirmation visits was different. In the current study we only used a single confirmation study 
whereas in our prior study we used multiple follow-up visits with urine collections. Whether 
confirmation of the transition endpoint at multiple visits would alter the results requires a study 
with multiple follow-up visits within a few months and this remains to be determined. In 
addition, the populations were different. In the current study we included patients with normo- 
and microalbuminuria as these individuals may progress in albuminuria stage. In our previous 
study patients with macroalbuminuria were included. Noteworthy, using single urine samples 
for albuminuria measurements without confirmation may increase the sensitivity to detect a 
transition but decrease specificity resulting in false positive and/or false negative results. In the 
context of a randomized controlled clinical trial this may increase data variability without 
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affecting the overall result of the trial. For the individual patient treated in clinical practice the 
increase in false positive and/or false negative results may hamper diagnostic and prognostic 
performance and may lead to erroneous conclusions whether the individual is at increased renal 
or cardiovascular risk.   
The limitations of our study are that we were only able to include clinical trials that 
assessed the effect of RAAS-intervention in patients with type 1 or type 2 diabetes. We do not 
know whether the results will be similar with other drugs or in other populations. To calculate 
a percentage increase in albuminuria we used the albuminuria values collected at a single 
baseline visit. Albuminuria was not assessed at multiple visits before randomization. We 
therefore do not know whether multiple baseline visits improved the precision in the percentage 
increase in albuminuria and the potential impact on the results. Thirdly, urine collections did 
not occur more frequently than every 6 months in all trials. We were therefore unable to 
determine whether shorter time-intervals between visits would lead to more significant 
treatment effects. Finally, these results were derived post-hoc. We encourage clinical trialists 
to prospectively validate these findings.   
In conclusion, neither increasing the number of urines collected at a single study visit, 
nor the inclusion of a confirmation visit, nor the time to the confirmation visit, nor the addition 
of a minimal required percentage albuminuria change altered the average drug effect. 
Therefore, we conclude that future clinical trials in diabetic nephropathy using albuminuria 
transitions as endpoint should consider single urine collections per study visit spaced no more 
than 6 months apart for albuminuria assessment. 
 
Concise methods 
Patients and clinical trials 
Data from four randomized controlled clinical trials in patients with type 1 or type 2 diabetes 
were analyzed: BENEDICT (Bergamo Nephrologic Diabetes Complications Trial), DIRECT 
(The Diabetic Retinopathy Candesartan Trials), ALTITUDE (Aliskiren Trial in Type 2 
Diabetes Using Cardio-renal Endpoints), and IRMA-2 (Irbesartan in patients with type 2 
diabetes and Microalbuminuria) trials were included in this study. All trials assessed the effect 
of intervention in the renin-angiotensin-aldosterone-system on progression of albuminuria. The 
study designs and results of each trial are reported elsewhere and here briefly described 
.3,6,11,12,16 
In the BENEDICT trial 1209 patients with type 2 diabetes, normoalbuminuria (urinary 
albumin excretion rate < 20μg/min) and serum creatinine ≤ 1.5mg/dL were randomly allocated 
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to placebo or active treatment with either verapamil (240 mg/day), trandolapril (2mg/day) or 
the combination of verapamil 180 mg/day and trandolapril 2mg/day. Since the effect of 
trandalopril and trandolapril/verapamil in delaying progression to microalbuminuria were 
similar, we combined both treatment arms in order to increase statistical power and compared 
against placebo. Patients with microalbuminuria at baseline were excluded from analysis. 
Urinary albumin excretion was assessed at randomization and every six months during the 3.6 
years median follow-up.4,11 
The DIRECT trial was a clinical trial program consisting of three clinical trials in 3326 
type 1 diabetes patients with or without retinopathy and in 1905 type 2 diabetes patients with 
retinopathy. Patients had normo-albuminuria (urinary albumin excretion rate < 20μg/min) and 
serum creatinine ≤ 1.5mg/dL and ≤ 1.1mg/dL (for men and women respectively). In the 
DIRECT trial patients were randomly allocated to placebo or treatment with candensartan (16 
mg/day increasing to 32 mg/day according to tolerability) and followed for a median time of 
4.7 years.12 Albuminuria was assessed at randomization and yearly during follow-up.5 Patients 
with missing baseline albuminuria or microalbuminuria at baseline were excluded from 
analysis leaving 3095 type 1 and 1795 type 2 diabetes patients available for analysis. 
The ALTITUDE trial was a randomized, double-blind, placebo-controlled trial 
enrolling 8561 patients with type 2 diabetes mellitus at high risk for cardiovascular and renal 
events. Eligible patients had either persistent macroalbuminuria (defined in this trial as 
urinary albumin/creatinine ratio (UACR) ≥200 mg/g), or an estimated glomerular filtration 
rate (eGFR) ≥30 to ≤60 mL/min/1.73m2 combined with either persistent microalbuminuria 
(UACR ≥20 mg/g to ≤200) mg/g or a history of cardiovascular disease. Patients were 
randomly assigned to aliskiren 300 mg/day or matched placebo in addition to an optimal 
recommended dose of an angiotensin converting enzyme inhibitor (ACEi) or angiotensin 
receptor blocker (ARB).  For the purpose of this study we excluded patients in the 
ALTITUDE trial who had UACR > 300 mg/g at baseline (n=4493) and those with missing 
baseline albuminuria measurements or no follow-up measurements (n=384) leaving 3654 
patients available for analysis. Albuminuria was assessed at randomization, every 3 months 
during the first year and every 6 months thereafter. Randomized patients were followed for a 
median of 32.9 months for occurrence of cardiovascular and renal events.6,16 
In the IRMA-2 trial, 590 patients with type 2 diabetes, micro-albuminuria (urinary 
albumin excretion rate > 20 to 200μg/min) and serum creatinine ≤ 1.5mg/dL and ≤ 1.1mg/dL 
(for men and women respectively) were enrolled. Patients were randomly allocated to either 
placebo or active treatment with irbesartan 150mg/day or 300mg/day. For the purpose of 
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analysis we combined the two irbesartan treatment arms to increase statistical power. Urinary 
albumin excretion was assessed at randomization and every six months during the 2 years 
follow-up.3 We included 565 patients without macroalbuminuria at baseline. 
 
Urine collections and albuminuria measurements 
The frequency of urine collections (single, double, or triple) per study visit as well as 
albuminuria assessment (i.e. spot or timed collection) differed in the four trials. In BENEDICT 
and ALTITUDE three consecutive urine collections for albuminuria assessment were 
performed at each study visit. In DIRECT two consecutive urine collections were performed 
at each study visit starting the day prior to the study visit. In IRMA-2 only single urine 
collections were performed at each study visit. In BENEDICT and ALTITUDE urinary 
albumin and creatinine were measured in first morning void urine collections. In DIRECT and 
IRMA-2 timed overnight urine collections were performed and urinary albumin excretion was 
measured. In each trial urinary albumin and creatinine were measured in a central laboratory. 
In this study we defined microalbuminuria as a UACR of 30 mg/g or urinary albumin excretion 
of 20 µg/min. Macroalbuminuria was defined as a UACR of 300 mg/g or urinary albumin 
excretion of 200 µg/min.  
 
Statistical analyses 
Baseline characteristics are presented as mean and standard deviation for continuous variables 
and as counts and proportions for discrete variables. Non-parametric data are presented as 
median and interquartile range. The number of albuminuria class transitions (progression from 
either normo- to micro or micro- to macroalbuminuria) were recorded and incidence rate per 
100 patient years was calculated. The effects of randomized treatment on all endpoint 
definitions were estimated from unadjusted Cox proportional hazard models, based on the 
intention to treat principle. For participants who experienced more than one event during 
follow-up, survival time to the first relevant endpoint was used in each analysis. Participants 
were censored at their date of death or, for those still alive, at the end of follow-up. The 
magnitude of the treatment effect is reflected by the hazard ratio and the precision of the 
treatment effect by its 95% confidence interval. We first determined whether increasing the 
number of consecutive urine collections at a single visit would lead to a more significant 
treatment effect. We subsequently determined the effect of the time-interval between visits, the 
addition of a confirmatory visit, and the addition of a percentage change in albuminuria from 
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baseline using the number of urine collections as defined in the first step. Unscheduled visits 
for albuminuria measurements were not included in the drug efficacy analyses.  
The association between a transition in albuminuria class (progression to micro-  or 
macroalbuminuria or regression to micro- or normoalbuminuria) during the first year of the 
trial and subsequent renal and cardiovascular outcomes was estimated using a multivariable 
Cox regression model. The Cox model was adjusted for age, gender, albuminuria, eGFR, 
systolic and diastolic blood pressure, HbA1c, and history of cardiovascular disease (yes/no).  
 All analyses were performed using SAS 9.3 for Windows (SAS Institute, Cary, NC). A 
two sided p-value < 0.05 was considered to indicate statistical significance.  
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Table 1: Baseline characteristics of the clinical trial populations 
 BENEDICT 
(N=742) 
DIRECT (T1D) 
(N=3093) 
DIRECT (T2D) 
(N=1758) 
ALTITUDE 
(N=3654) 
IRMA-2 
(N=565) 
Gender, Male (n, %) 397 (53.5) 1771 (57.3) 858 (48.1) 2497 (68.3) 391 (69.2) 
Age (years) 61.9 (8.0) 31.0 (8.4) 56.9 (7.7) 65.8 (9.4) 58.1 (8.6) 
Diastolic BP (mmHg) 88.8 (7.7) 73.1 (6.9) 78.0 (7.0) 74.1 (10.0) 89.6 (9.3) 
Systolic BP (mmHg) 152.4 (14.0) 116.9 (9.6) 132.7 (13.5) 138.2 (16.3) 152.7 (14.6) 
Albuminuria*  5.2 [3.5 – 8.8] †  4.5 [3.5 – 7.0] † 5 [3.5 – 8.0] † 23.7 [4.11 – 73.6]# 58.0 [33.0 – 102.0]#  
Normoalbuminuria 
(n,%) 
742 (100) 3093 (100) 1758 (100) 1020 (27.9) 0 (0) 
Microalbuminuria (n,%) 0 (0) 0 (0) 0 (0) 2634 (72.1) 565 (100) 
HbA1c (%) 3.0 (1.4) 8.3 (1.6) 8.2 (1.6) 7.9 (1.7) 7.0 (1.7) 
Tot. cholesterol (mg/dL) 211.8 (36.5) 184.8 (37.5) 204.9 (42.5) 170.5 (46.4) 223.2 (44.4) 
eGFR (mL/min/1.73m2)  81.4 (15.3) 80.8 (13.7) 70.0 (14.2) 55.4 (20.6) 70.5 (12.4) 
*Presented as median and IQR / #Urinary albumin:creatinine ratio mg/g / †Urinary albumin excretion rate µg/min 
13 
 
Table 2: Number of endpoints and event rates (events per 100 patient*years) for each clinical 
trial and endpoint definition 
 Single visit  confirmation* 
 1 measurement Mean of 2 measurements Mean of 3 measurements  1 measurement 
Normo- to microalbuminuria 
BENEDICT 123 (5.9)  107 (5.1) 98 (4.1)   14 (0.7)  
DIRECT (T1D) 441 (3.5) 344 (2.7) Na  100 (1.0) 
DIRECT (T2D) 431 (6.5) 380 (5.6) Na  159 (2.9) 
Micro- to macroalbuminuria 
IRMA-2† 114 (12.6) Na Na  26 (3.8) 
Normo- to micro- and micro- to macroalbuminuria 
ALTITUDE 1861 (33.1) 1738 (29.4) 1717 (29.0)  1087 (21.0) 
10% change in albuminuria in addition to a transition 
Normo- to microalbuminuria 
BENEDICT 123 (5.9)  107 (5.1) 98 (4.1)  14 (0.7) 
DIRECT (T1D) 440 (3.5) 344 (2.7) Na  100 (1.0) 
DIRECT (T2D) 431 (6.5) 380 (5.6) Na  159 (2.9) 
Micro- to macroalbuminuria 
IRMA-2 114 (12.6) Na Na  26 (3.8) 
Normo- to micro- and micro- to macroalbuminuria 
ALTITUDE 1858 (33.0) 1731 (29.3) 1713 (28.9)  1078 (20.7) 
30% change in albuminuria in addition to a transition 
Normo- to microalbuminuria 
BENEDICT 120 (5.7)  103 (4.9)  95 (4.0)  13 (0.7) 
DIRECT (T1D) 437 (3.4) 341 (2.6) Na  99 (1.0) 
DIRECT (T2D) 428 (6.4) 378 (5.6) Na  154 (2.8) 
Micro- to macroalbuminuria 
IRMA-2 113 (12.5) Na Na  25 (3.6) 
Normo- to micro- and micro- to macroalbuminuria 
ALTITUDE 1826 (32.0) 1704 (28.6) 1684 (28.1)  1045 (19.8) 
50% change in albuminuria in addition to a transition 
Normo- to microalbuminuria 
BENEDICT 112 (5.3)  100 (4.7)  88 (3.7)  13 (0.7) 
DIRECT (T1D) 431 (3.4) 339 (2.6) Na  99 (1.0) 
DIRECT (T2D) 421 (6.3) 372 (5.5) Na  146 (2.6) 
Micro- to macroalbuminuria 
IRMA-2 109 (12.0) Na Na  22 (3.2) 
Normo- to micro- and micro- to macroalbuminuria 
ALTITUDE 1754 (30.1) 1654 (27.2) 1636 (26.8)  989 (18.4) 
100% change in albuminuria in addition to a transition 
Normo- to microalbuminuria 
BENEDICT 95(4.5)  80 (3.8) 73 (3.0)   8 (0.4) 
DIRECT (T1D) 409 (3.2) 316 (2.4) Na  93 (0.9) 
DIRECT (T2D) 391 (5.8) 351 (5.1) Na  131 (2.3) 
Micro- to macroalbuminuria 
IRMA-2 95 (10.4) Na Na  20 (2.9 
Normo- to micro- and micro- to macroalbuminuria 
ALTITUDE 1628 (26.5) 1504 (23.5) 1493 (23.3)  849 (15.3) 
*Confirmation of transition endpoint at a subsequent study visit. The confirmation is based on a single urine 
sample obtained at the initial and confirmation visit.  
†In the IRMA-2 trial only single urine collections were performed at each visit  
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Figure 1: Magnitude and precision of the drug effect estimate according the number 
of urine collections at a single study visit. Solid circles represents the estimate of the 
treatment effect and the horizontal line indicates the 95% confidence interval.  
 
 
 
 
 
 
Favors Favors
RAASi Placebo RAASi Placebo
BENEDICT
1 urine collection 74/14.5 49/21.0
2 urine collections 63/12.4 44/18.9
3 urine collections 57/11.2 41/17.6
DIRECT Type 1
1 urine collection 217/14.1 224/14.4 0.96 (0.80 - 1.16 )
2 urine collections 165/10.7 179/11.5 0.92 (0.74 - 1.13 )
DIRECT Type 2
1 urine collection 197/22.3 234/26.7 0.79 (0.66 - 0.96 )
2 urine collections 174/19.7 206/23.5 0.80 (0.65 - 0.98 )
ALTITUDE
1 urine collection 850/46.4 1011/54.6 0.79 (0.72 - 0.86 )
2 urine collections 789/43.0 949/52.1 0.80 (0.73 0.88 )
3 urine collections 776/42.3 941/50.6 0.78 (0.71 0.86 )
No / % of  events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 (0.46 - 0.94 )
0.61 (0.42 - 0.90 )
0.60 (0.40 - 0.89 )
0.5 0.8 1 1.2 1.5
-
-
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Figure 2: Magnitude and precision of the drug effect estimate with a single urine collection 
and unconfirmed andwith and without a confirmatory visit. Solid circles represents the estimate 
of the treatment effect and the horizontal line indicates the 95% confidence interval.  
 
 
  
Favors Favors
RAASi Placebo RAASi Placebo
BENEDICT
unconfirmed 74/14.5 49/21.0
confirmed 8/1.7 6/2.8
DIRECT Type 1
unconfirmed 217/14.1 224/14.4 0.96 (0.80 - 1.16 )
confirmed 49/3.3 51/3.4 0.96 (0.65 - 1.42 )
DIRECT Type 2
unconfirmed 197/22.3 234/26.7 0.79 (0.66 - 0.96 )
confirmed 77/9.8 82/9.1 0.93 (0.68 - 1.26 )
IRMA-2
unconfirmed 64/17.2 50/25.9
confirmed 14/4.0 12/7.0
ALTITUDE
unconfirmed 850/46.4 1011/54.6 0.79 (0.72 - 0.86 )
confirmed 458/26.3 629/35.5 0.71 (0.63 0.80 )
No. / % of  events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
-
0.66 (0.46 - 0.94 )
0.59 (0.21 - 1.70 )
0.59 (0.41 0.86 )
0.51 (0.23 1.10 )
-
-
0.2 0.3 0.5 0.8 1 1.2 1.5 2
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Figure 3: Magnitude and precision of the drug effect estimate with a single urine collection  
and various percentage change in albuminuria increases on top of the class transition without 
a confirmatory visit. Solid circles represents the estimate of the treatment effect and the 
horizontal line indicates the 95% confidence interval.  
 
 
Favors Favors
RAASi Placebo RAASi Placebo
BENEDICT
0% 74/14.5 49/21.0
10% 74/14.5 49/21.0
30% 72/14.1 48/20.6
50% 67/13.2 45/19.3
100% 53/10.4 42/18.0
DIRECT Type 1
0% 217/14.1 224/14.4 0.96 ( 0.80 - 1.16 )
10% 217/14.1 223/14.3 0.97 ( 0.80 - 1.16 )
30% 215/14.0 222/14.3 0.96 ( 0.80 - 1.16 )
50% 213/13.9 218/14.0 0.97 ( 0.80 - 1,17 )
100% 207/13.5 202/13.0 1.02 ( 0.84 - 1.24 )
DIRECT Type 2
0% 197/22.3 234/26.7 0.79 ( 0.66 - 0.96 )
10% 197/22.3 234/26.7 0.79 ( 0.66 - 0.96 )
30% 195/22.1 233/26.6 0.79 ( 0.65 - 0.95 )
50% 191/21.6 230/26.3 0.78 ( 0.64 - 0.94 )
100% 175/19.8 216/24.7 0.76 ( 0.62 - 0.94 )
IRMA-2
0% 64/17.2 50/25.9
10% 64/17.2 50/25.9
30% 64/17.2 49/25.4
50% 63/16.9 46/23.8
100% 57/15.3 38/19.7
ALTITUDE
0% 850/46.4 1011/54.6 0.79 ( 0.72 - 0.86 )
10% 848/46.3 1010/54.6 0.79 ( 0.72 - 0.86 )
30% 828/45.2 998/53.9 0.78 ( 0.71 - 0.86 )
50% 795/43.4 959/51.8 0.79 ( 0.71 - 0.86 )
100% 725/39.6 903/48.7 0.76 ( 0.69 - 0.84 )
No. / % of  events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 ( 0.46 - 0.94 )
0.66 ( 0.46 - 0.94 )
0.65 ( 0.45 - 0.94 )
0.65 ( 0.44 - 0.94 )
0.54 ( 0.36 - 0.81 )
0.59 ( 0.41 - 0.86 )
0.59 ( 0.41 - 0.86 )
0.61 ( 0.42 - 0.88 )
0.63 ( 0.43 - 0.92 )
0.69 ( 0.46 - 1.04 )
0.5 0.8 1 1.2 1.5
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Supplement Table 13: Association between a transition in albuminuria class (normo- to microalbuminuria transition or micro- to 
macroalbuminuria transition) during the first year of the ALTITUDE trial with subsequent renal (doubling serum creatinine / end-stage renal 
disease / renal death) and cardiovascular (CV-death, resuscitated sudden death, myocardial infarction, stroke, unplanned hospitalization for heart 
failure) outcomes. The definitions of albuminuria class transitions are similar as those that were used to assess the drug effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The presented hazard ratios are derived from a Cox proportional hazard models and adjusted for age, gender, albumin:creatinine ratio, eGFR, systolic/diastolic 
blood pressure, HbA1c, and cardiovascular disease history.   
The composite renal endpoint was defined as end-stage renal disease, defined as the need for chronic dialysis or renal transplantation; renal death 
defined as the need for renal-replacement therapy with no dialysis or transplantation available or initiated; doubling of serum creatinine from 
baseline sustained for at least a month. The composite cardiovascular endpoint was defined as death from cardiovascular causes or the first 
occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; or unplanned hospitalization for heart failure. All 
clinical endpoints were adjudicated by a central endpoint committee utilizing standard definitions. 
  
  Renal outcome Cardiovascular outcome 
  Hazard Ratio (95%CI) Chi2 P Hazard Ratio (95%CI) Chi2 P 
Single visit:        
Single urine sample  1.92 (1.09; 3.40) 5.02 0.025 1.45 (1.15; 1.83) 9.81 0.002 
Two urine samples  1.80 (1.01; 3.20) 3.98 0.046 1.30 (1.02; 1.65) 4.46 0.035 
Three urine samples  1.82 (1.02; 3.24) 4.12 0.042 1.35 (1.06; 1.72) 6.00 0.014 
Addition of confirmation visit  2.47 (1.36; 4.49) 8.81 0.003 1.42 (1.09; 1.85) 6.84 0.009 
Transition + 10% UACR increase   1.94 (1.10; 3.43) 5.19 0.023 1.44 (1.14; 1.82) 9.45 0.002 
Transition + 20% UACR increase  1.97 (1.11; 3.48) 5.44  0.020 1.42 (1.12; 1.80) 8.65 0.003 
Transition + 30% UACR increase  2.06 (1.17; 3.64) 6.20 0.013 1.39 (1.10; 1.76) 7.47 0.006 
Transition + 40% UACR increase  2.13 (1.21; 3.76) 6.81 0.009 1.42 (1.12; 1.79) 8.43 0.004 
Transition + 50% UACR increase  2.22 (1.26 – 3.91) 7.59 0.006 1.36 (1.07 – 1.72) 6.39 0.012 
Transition + 100% UACR increase  1.98 (1.11 – 3.51) 5.42 0.020 1.30 (1.02 – 1.66) 4.39 0.036 
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Supplement Figure 1: Magnitude and precision of the drug effect estimate with a single urine 
collection and different time-intervals between study visits. Solid circles represents the 
estimate of the treatment effect and the horizontal line indicates the 95% confidence interval. 
 
 
  
Favors Favors
RAASi Placebo RAASi Placebo
BENEDICT
6 months 74/14.5 49/21.0
12 months 39/8.3 28/12.9
ALTITUDE
6 months 850/46.41 1011/54.6 0.79 (0.72 - 0.86 )
12 months 710/40.3 863/47.8 0.78 (0.71 - 0.87 )
IRMA-2
6 months 64/17.2 50/26.3
12 months 30/8.6 24/14.0
No / % of  events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.66 (0.46 - 0.99 )
0.61 (0.38 - 1.00 )
0.59 (0.41 - 0.86 )
0.52 (0.30 - 0.89 )
0.3 0.5 0.8 1 1.2 1.5
19 
 
Supplement Figure 2: Magnitude and precision of the drug effect estimate with a single 
urine collection  and various percentage albuminuria increases without a class transition and 
without a confirmatory visit. Solid circles represents the estimate of the treatment effect and 
the horizontal line indicates the 95% confidence interval.  
 
  
Favors Favors
RAASi Placebo RAASi Placebo
BENEDICT
50% 248/48.7 120/51.5
100% 150/29.5 84/36.1
DIRECT Type 1
50% 968/62.6 915/58.5 1.10 ( 1.00 - 1,20 )
100% 706/45.7 669/42.8 1.08 ( 0.97 - 1.20 )
DIRECT Type 2
50% 566/63.4 521/70.2 0.80 ( 0.72 - 0.90 )
100% 425/47.6 469/53.0 0.83 ( 0.73 - 0.94 )
IRMA-2
50% 168/45.2 123/63.7
100% 123/33.1 81/42.0
ALTITUDE
50% 2136/43.4 2939/51.8 0.82 ( 0.77 - 0.87 )
100% 1626/39.6 2587/48.7 0.80 ( 0.75 - 0.85 )
No. / % of  events
Hazard Ratio (95% CI)
Hazard ratio (95% CI)
0.90 ( 0.73 - 1.13 )
0.78 ( 0.60 - 1.02 )
0.52 ( 0.41 - 0.66 )
0.66 ( 0.50 - 0.88 )
0.5 0.8 1 1.2 1.5
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